Please use this identifier to cite or link to this item:
|Title:||Cancer vaccines: Where are we going?|
|Authors:||Cebon, Jonathan S|
|Affiliation:||Austin Ludwig Oncology Unit, Ludwig Institute, Melbourne, Victoria, Australia. email@example.com|
|Citation:||Asia-pacific Journal of Clinical Oncology; 6 Suppl 1(): S9-15|
|Abstract:||Abstract The discovery that the immune system can distinguish molecular targets on cancer cells has led to efforts to develop cancer immunotherapeutics that can improve the recognition and effective elimination of tumor cells. Several types of tumor antigens are recognized by T lymphocytes, which are classified according to patterns of gene expression or protein distribution. Of particular interest is the group of molecules known as cancer-germline or cancer-testis antigens. As the relationship between the immune system and cancer has become clearer, so too have the challenges in designing effective cancer immunotherapeutics: (i) antigens need to be specifically selected based on ideal characteristics, such as tissue distribution that is restricted to tumors; (ii) selected antigens need to be combined with adjuvant agents that enhance their immunogenicity and yield robust responses; (iii) vaccination should be timed to pre-empt the development of regulatory suppressive immune mechanisms; and (iv) if suppressive regulatory mechanisms do arise, specific antagonists may be needed to enhance pro-immune outcomes. These challenges are shaping current and future research in this area.|
|Internal ID Number:||20482531|
Cancer Vaccines.immunology.therapeutic use
Clinical Trials as Topic
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.